PT-141 (Bremelanotide): melanocortin agonism and the central arousal pathway

PT-141, known generically as Bremelanotide, is a cyclic seven-amino-acid peptide derived from the α-MSH analog Melanotan II. Where Melanotan II was originally explored as a tanning agent — via activation of MC1R on melanocytes — researchers noted that test subjects reported unrelated and unintended effects on sexual arousal. This observation was traced to the compound’s activity at the central melanocortin receptors MC3R and MC4R, and a medicinal-chemistry program was initiated to produce a derivative with reduced MC1R activity (to avoid pigmentation) and retained central activity. The result was PT-141 [1, 7].

Bremelanotide is unusual among research peptides in that it completed Western regulatory trials and was approved by the FDA in 2019 for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women, under the brand name Vyleesi. The approval was based on the RECONNECT trials reported by Kingsberg et al. [5]. This context is relevant because it provides a human pharmacological and safety literature that is atypically complete for a compound still frequently encountered in research-peptide catalogs.

PT-141 acts as a non-selective agonist at the family of melanocortin receptors, with principal activity at MC3R and MC4R and reduced but non-zero activity at MC1R. The MC4R subtype is densely expressed in hypothalamic regions involved in sexual behavior, appetite regulation, and autonomic tone. MC3R is broadly distributed in limbic structures [1].

Unlike PDE5 inhibitors (sildenafil, tadalafil) which act peripherally on penile or clitoral vascular smooth muscle, PT-141 is a central-acting agent. The rodent literature established this distinction clearly: Pfaus and colleagues demonstrated in female rats that a melanocortin agonist selectively facilitated sexual solicitation behavior independently of peripheral vascular mechanisms [3]. This positions PT-141 as a candidate therapeutic for arousal disorders with a primarily central rather than peripheral origin.

Wessells et al. (2003) summarized early human studies with PT-141 and its predecessor Melanotan II, demonstrating facilitation of erectile response and subjective arousal in men and women [7]. Rosen et al. (2004) characterized the safety, pharmacokinetics, and pharmacodynamics of subcutaneous PT-141 in healthy male subjects, establishing the dose-response relationship that informed later clinical trials [2].

Downstream, MC4R activation engages oxytocinergic and dopaminergic pathways in the hypothalamus, which are closely tied to the motivational and reward aspects of sexual behavior. The compound is therefore sometimes described as acting on the “desire” phase of arousal rather than on vascular engorgement per se.

Early human trials (2000s). Rosen and colleagues (2004) established safety and pharmacokinetic profile in healthy men [2]. Diamond et al. (2006) reported on subjective sexual response in premenopausal women with sexual arousal disorder, with positive signal on self-reported arousal endpoints [4]. These trials used subcutaneous and intranasal routes; the intranasal route was later deprioritized in development in favor of subcutaneous, partly due to variability in nasal absorption in a large-N clinical program.

Phase 2 dose finding. Clayton et al. (2016) reported a randomized placebo-controlled dose-finding trial in premenopausal women with female sexual dysfunction, establishing the dose range that advanced to phase 3 [6].

RECONNECT (phase 3). Kingsberg and colleagues (2019) reported two randomized phase-3 trials in a combined population of over 1,200 premenopausal women with HSDD [5]. Both trials met primary endpoints on the validated Female Sexual Function Index and Female Sexual Distress Scale. This dataset is the foundation of the FDA approval.

Safety. The most commonly reported adverse events in the phase-3 program were nausea (transient, often limited to first doses), flushing, headache, and transient increases in blood pressure. A minority of patients exhibited focal hyperpigmentation with repeated dosing — an expected pharmacological consequence of residual MC1R activity. Cardiovascular safety is the principal contraindication consideration in the regulatory label [5].

Intranasal PT-141 was extensively studied in early development and was the route used in several early phase-2 trials [4, 7]. It was ultimately deprioritized in favor of subcutaneous injection for the approved product (Vyleesi), primarily due to inter-subject variability in nasal absorption at the scale of a large Phase-3 program — not due to failure of the route.

For research-protocol purposes, intranasal PT-141 remains of interest because the route offers rapid onset, avoidance of injection, and exploitation of the olfactory/trigeminal pathway for CNS-targeted delivery. Plasma concentration curves from the intranasal literature are generally characterized by faster Tmax than subcutaneous and lower absolute bioavailability — a typical nasal-peptide profile.

Researchers working with intranasal PT-141 should be aware that individual nasal physiology is a larger source of pharmacokinetic variance for this compound than for, e.g., Selank or Semax — one of the reasons the developer shifted to subcutaneous for approval.

Research-grade PT-141 under HPLC-verified purity is catalog-listed at /products/pt-141-nasal-spray.

PT-141 operates on a specific and dense hypothalamic pathway, which informs stack design more than most peptides:

• Other melanocortin agonists (Melanotan II, etc.) — not combined. There is overlapping receptor activity and potential for additive cardiovascular and pigmentation effects.
• PDE5 inhibitors — the pharmacology is non-overlapping (central vs. peripheral), but the cardiovascular safety combination has been explicitly discussed in the regulatory literature; caution on blood-pressure interactions applies [5].
• BPC-157, Selank, Semax — mechanism- orthogonal and not expected to interact at the pharmacological level. Researchers nonetheless typically separate intranasal sessions to avoid confounding formulation effects. See our stack protocols entry.